The ongoing cuts in global aid from the US and other donors could lead to 9.4 million additional deaths by 2030 if current trends continue.

Close to half of the CDC surveillance databases which were previously updated monthly were then paused as of 2025.

HealthDay News — The prevalence of obesity is high in the United States and is expected to continue increasing to 46.9 percent of the adult population by 2035, according to a study published online ...

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...

Significant predictors of 28-day mortality in critically ill patients with systemic sclerosis include male sex and BMI.

Biologic therapies are safe for use in patients with psoriasis who also have active or recent cancer when compared with conventional therapies.

The most common cancers in men were prostate, lung, melanoma, bladder, and colon and in women were breast, lung, uterus, colon, and melanoma.

The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.

Health care providers can take steps to protect patients targeted by ICE, ensuring that patients retain their privacy and ...

HealthDay News — For patients with desmoplastic melanoma, neoadjuvant treatment with pembrolizumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, results in a pathological complete response ...

The FDA grants Fast Track designation to sonelokimab for moderate to severe palmoplantar pustulosis, a chronic inflammatory skin disease.

Though SE was the most effective therapy for Bowen disease, the risk for recurrence with 5-FU and MAL-PDT was negligible.